


**Supplementary Figures.**



**Figure 1S. CPE-VNT validation and *in house* evaluation of the study selected samples.** The 382 samples previously selected for validation were evaluated by CPE-VNT regarding neutralizing antibodies and subsequently tested by three *in house* ELISA methodologies (N-ELISA, ΔS1-ELISA and RBD-ELISA) for detection of SARS-CoV-2 specific antibodies. The figure shows a flow chart indicating CPE-VNT and ELISA positive and negative samples.



**Figure 2S. Flow chart representing sample selection for the study.** Elecsys® Anti-SARS-CoV-2 Immunoassay evaluated samples were selected for the study based on positive, inconclusive or negative results.



**Figure 3S. Heat map of discrepant results between assays.** The heat map represents, from light green to red colors, the respective crescent number of samples that had different results when evaluated by the assays of the study.

**Supplementary Table.**

**Table S1. Inconclusive Elecsys results for CPE-VNT, N-ELISA, ΔS1-ELISA and RBD-ELISA tests.**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Sample ID** | **Elecsys anti-SARS-CoV-2 immunoassay** | **CPE-VNT**  **\*** | **N-ELISA**  **\*\*** | **ΔS1-ELISA**  **\*\*\*** | **RBD-ELISA**  **\*\*\*\*** |
| 0886625101 | Inconclusive | **-** | **-** | **+** | **-** |
| 0886574301 | Inconclusive | **-** | **-** | **-** | **-** |
| 0886667501 | Inconclusive | **+** | **-** | **+** | **+** |
| 0886677001 | Inconclusive | **-** | **-** | **-** | **-** |
| 0886630401 | Inconclusive | **-** | **-** | **-** | **-** |
| 0886618801 | Inconclusive | **+** | **+** | **+** | **+** |

\* Positive (+) = VNT100 ≥ 20; Negative (-) = VNT100 < 20

\*\* (+) = OD ≥ 0.554; (-) = OD < 0.554

\*\*\* (+) = OD ≥ 0.528; (-) = OD < 0.528

\*\*\*\* (+) = OD ≥ 0.336; (-) = OD < 0.336